To establish a Biotechnology Management Office in the Department of Defense and to provide support for the research and development of bioindustrial manufacturing processes, and for other purposes.

HR 6664 establishes a Biotechnology Management Office within the Department of Defense to coordinate and advance biotechnology capabilities. The office, led by a senior official with biotech expertise, will create a long-term development roadmap, update Department policies on biotech products, coordinate with industry and academia, and identify workforce gaps. It directly affects Defense Department operations by streamlining R&D funding for bioindustrial manufacturing processes under existing NDAA authorities. The office is temporary, terminating on September 30, 2030, and requires congressional briefings on its implementation.